Suven Life Sciences begins Masupirdine phase 3 clinical trial in dementia patients
Suven Life Sciences has started a global phase 3 clinical trial of Masupirdine in dementia of the Alzheimer’s type by randomizing the first patient. According to the Indian biopharma company, the late-stage trial of the serotonin-6 (5-HT6) receptor antagonist is a double-blind, placebo-controlled study intended to be held in 50 sites in North America and […]